user

IMPACT OF IMPROVED TREATMENT COMPLIANCE WITH DELAYED-RELEASE CYSTEAMINE BITARTRATE CAPSULES ON THE COSTS OF END STAGE RENAL DISEASE FOR PATIENTS WITH NEPHROPATHIC CYSTINOSIS IN THE UNITED KINGDOM

被引：0
|
作者：
Lashilola, Seun [1 ]
Xu, Weiwei [1 ]
Brandi, Giacomo [2 ]
Azimpour, Khashayar [2 ]
Carlot, Sara [2 ]
机构：
[1] Iqvia, Durham, NC USA
[2] Chiesi, Parma, Italy
来源：
PEDIATRIC NEPHROLOGY | 2022年 / 37卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R72 [儿科学];
学科分类号：
100202 ;
摘要：
EP-119
引用
收藏
页码：2909 / 2910
页数：2
相关论文
共 8 条
  • [1] Long-term clinical benefits of delayed-release cysteamine bitartrate capsules in patients with nephropathic cystinosis (response to "A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis")
    Langman, Craig B. B.
    ORPHANET JOURNAL OF RARE DISEASES, 2023, 18 (01)
  • [2] Long-term clinical benefits of delayed-release cysteamine bitartrate capsules in patients with nephropathic cystinosis (response to “A comparison of immediate release and delayed release cysteamine in 17 patients with nephropathic cystinosis”)
    Craig B. Langman
    Orphanet Journal of Rare Diseases, 18
  • [3] Fibrosing colonopathy associated with cysteamine bitartrate delayed-release capsules in cystinosis patients
    Kishk, Omayma A.
    Kim, Ivone
    Cheng, Carmen
    Summan, Mukesh
    Munoz, Monica A.
    PEDIATRIC NEPHROLOGY, 2024, 39 (08) : 2429 - 2433
  • [4] Impact of compliance to oral cysteamine treatment on the costs of Kidney failure in patients with nephropathic cystinosis in the United Kingdom
    Lashilola, Seun
    Xu, Weiwei
    Azimpour, Khashayar
    McCarthy, Michael
    Carlot, Sara
    Game, David
    van der Voort, Judith
    BMC NEPHROLOGY, 2023, 24 (01)
  • [5] Impact of compliance to oral cysteamine treatment on the costs of Kidney failure in patients with nephropathic cystinosis in the United Kingdom
    Seun Lashilola
    Weiwei Xu
    Khashayar Azimpour
    Michael McCarthy
    Sara Carlot
    David Game
    Judith van der Voort
    BMC Nephrology, 24
  • [6] Quality of Life is Improved and Kidney Function Preserved in Patients with Nephropathic Cystinosis Treated for 2 Years with Delayed-Release Cysteamine Bitartrate
    Langman, Craig B.
    Greenbaum, Larry A.
    Grimm, Paul
    Sarwal, Minnie
    Niaudet, Patrick
    Deschenes, Georges
    Cornelissen, Elisabeth A. M.
    Morin, Denis
    Cochat, Pierre
    Elenberg, Ewa
    Hanna, Christian
    Gaillard, Segolene
    Bagger, Mary Jo
    Rioux, Patrice
    JOURNAL OF PEDIATRICS, 2014, 165 (03): : 528 - +
  • [7] An Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Cysteamine Bitartrate Delayed-release Capsules (RP103), Compared to Cysteamine Bitartrate Capsules, (Cystagon®) in Patients with Nephropathic Cystinosis
    Rioux, P.
    Barshop, B.
    PEDIATRIC NEPHROLOGY, 2010, 25 (10) : 2197 - 2197
  • [8] An Open-Label, Dose-Escalation Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of Cysteamine Bitartrate Delayed-release Capsules (RP103) for Treatment of Children with Inherited Mitochondrial Disease (RP103-MITO-001)
    Cohen, Bruce H.
    Enns, Gregory M.
    Haas, Richard
    Longo, Nicola
    Scaglia, Fernando
    Lang, William
    Sile, Saba
    MITOCHONDRION, 2016, 31 : 117 - 117
1